sunitinib,nivolumab
bms,pfizer
['sunitinib', ' cis ', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'nivo']
 caution using hr vs sunitinib to compare io+io to tki io in fav risk across trials. nivo 2nd line was approved 3 mo before 214 closed accrual, but before all 3 of the tki+io trials launched. fewer of the 214 sunitinib pts had access to salvage nivo. and cis all cross 1. #gu23 
Deputy Director @FoxChaseCancer. Professor GU Med Onc. @ASCO BOD 2020-24. Views mine. COI: https://t.co/fmmRpMCIWd